


# EndoPredict®

## Breast Cancer Prognostic Test by Myriad Genetics

"Source BioScience is delighted to partner with Myriad to provide the NICE-approved breast cancer multigene assay, EndoPredict, in the UK. Our long-established molecular pathology reference laboratory team will be able to provide a very timely service for lymph node negative and positive breast cancer patients and their clinical professionals, supporting effective adjuvant therapy decision making."

**- Professor Ian O Ellis, Professor of Cancer Pathology and Medical Director at Source BioScience**



### Added value:

- ✓ NICE Approved and cost recoverable test (Node -)
- ✓ Rapid TAT of 5 working days / 1 MDT Cycle. Patients can get results / treatment decisions quicker
- ✓ Approved by insurers (AXA & BUPA)
- ✓ UK based test, remove the risk of releasing patient material and data outside of the UK
- ✓ All patients are classified as high risk or low risk, unlike other tests which have a 'gray' middle area
- ✓ Increased confidence in treatment decisions
- ✓ Late reoccurrence, can predict late reoccurrence up to 15 years vs alternative test which are only up to 10
- ✓ Not stage dependent, suitable for stage 1, 2 and 3 cancers


Source BioScience is now the only distributor offering **Myriad Genetics EndoPredict** test to the UK market. This allows us to facilitate rapid and cost effective testing for patients without the need to release human tissue outside of the UK/EU, allowing you to process your samples locally, contributing to lower emissions and faster turnaround times.

## How to Order



### ORDER

Place order through  
Precision Medicine Portal



### SUBMIT SAMPLES



### ANALYSE

Results will be provided in  
5 working days



### RESULTS

Sign in to our secure  
Precision Medicine Portal  
to receive results

## Clinical information:

Molecular diagnostic testing has become routine in clinical practice to support the development of effective treatment plans for Cancer patients. For Breast Cancer patients **NICE** recommends prognostic tests such as **EndoPredict** to assess the risk of disease recurrence and the effectiveness of adjuvant **chemotherapy** in addition to **endocrine therapy**.

**EndoPredict** is the only prognostic test that can help in deciding whether your patient can safely avoid chemotherapy, how beneficial chemotherapy would be, and whether your patient can stop endocrine therapy after 5 years.

**EndoPredict** is designed for women with ER+, HER2- primary breast cancer (node-negative or node positive [micrometastases, 1-3 nodes], pre- or postmenopausal).

To find out more:

[enquiries@sourcebioscience.com](mailto:enquiries@sourcebioscience.com)

+44 (0) 115 973 9012

[sourcebioscience.com](http://sourcebioscience.com)

 Myriad  
genetics



0000

